Loading...

Financial Summary


Apollo Endosurgery Inc.

Apollo Endosurgery Inc. (APEN)

Healthcare
Buy
A-
Market Info
Financial Info
Financial Modelling
Symbol APEN
Price 2.66$
Beta 0.74
Volume Avrg. 0.03M
Market Cap 0.05B
Shares (2018) 19,789.87K
Last Div 0
Dividend Yield -
DCF Unlevered -25,875.78 Strong Sell
DCF Levered -29,592.28 Strong Sell
ROE -158.82% Strong Sell
ROA -154.85% Strong Sell
Operating Margin -55.48% Strong Sell
Debt / Equity 73.50% Buy
P/E - Neutral
P/B 2.62 Strong Buy

Income Statement

Download APEN income statement Download APEN income statement
Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Earnings Per Share Basic 37.73-43.12-26.95-20.02-37.73-77.00-151.90-105.69-2.01-2.31
Net Profit Margin 0.33-0.59-0.33-0.41-0.82-3.26-0.40-0.64-0.42-0.75
Earnings Per Share Diluted 37.73-43.12-26.95-20.02-37.73-77.00-151.90-105.69-2.01-2.31
Revenue 11.917.849.396.697.995.0867.7964.6564.3160.85
Weighted Average Shares Outstanding 0.100.100.110.140.170.250.420.4417.2921.89
Gross Profit 11.917.849.396.697.995.0847.2839.4039.7333.19
Weighted Average Shares Outstanding (Diluted) 0.100.100.120.140.170.220.240.3913.5719.79
Sales, General and Administrative Expense 3.484.503.374.094.234.7647.5845.1646.6346.27
Dividend per Share ----------
Operating Income 1.80-4.49-3.71-5.56-7.59-17.81-17.35-22.61-22.48-33.76
Gross Margin 1.001.001.001.001.001.000.700.610.620.55
Earnings before Tax 3.98-4.60-3.11-2.75-6.56-16.56-27.38-40.78-26.99-45.60
EBITDA Margin 0.35-0.57-0.32-0.38-0.80-3.22-0.14-0.21-0.20-0.53
Net Income 3.98-4.60-3.11-2.75-6.56-16.56-27.43-41.17-27.29-45.79
EBIT Margin 0.33-0.59-0.33-0.41-0.82-3.26-0.26-0.35-0.35-0.68
Net Income - Discounted ops ----------
Profit Margin 0.33-0.59-0.33-0.41-0.82-3.26-0.54-0.64-0.42-0.75
Preferred Dividends ------8.95---
Free Cash Flow margin -0.00-0.000.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
R&D Expenses 6.637.829.738.1611.3418.139.567.808.3012.18
Interest Expense ------10.0418.174.514.06
Earnings Before Tax Margin 0.33-0.59-0.33-0.41-0.82-3.26-0.40-0.63-0.42-0.75
Consolidated Income 3.98-4.60-3.11-2.75-6.56-16.56-27.43-41.17-27.29-45.79
EBIT 3.98-4.60-3.11-2.75-6.56-16.56-17.35-22.61-22.48-41.53
EBITDA 4.16-4.44-2.97-2.56-6.37-16.34-9.29-13.52-12.76-32.24
Income Tax Expense ------0.050.390.300.19
Operating Expenses 10.1112.3213.1012.2515.5822.8964.6362.0162.2166.96
Cost of Revenue ------20.5125.2524.5827.66
Net Income Com 3.98-4.60-3.11-2.75-6.56-16.56-36.38-41.17-27.29-45.79
Net Income - Non-Controlling int ----------

Balance Sheet Statement

Download APEN income statement Download APEN income statement
Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Total current liabilities 1.899.4210.078.633.534.2621.3020.2825.8324.45
Other Liabilities 1.638.937.867.601.511.3911.556.637.509.16
Long-term debt ------69.8039.4333.3221.19
Cash and cash equivalents 6.176.8014.4124.6211.8517.2822.5920.0431.4225.01
Total debt 0.02-----69.8039.4333.3221.19
Cash and short-term investments 6.176.8014.4124.6211.8517.2822.5920.0431.4225.01
Deferred revenue 0.6613.889.625.830.500.13----
Inventories ------12.7912.1614.349.93
Tax Liabilities ----------
Goodwill and Intangible Assets 0.901.331.611.691.932.2449.1750.1443.2515.15
Deposit Liabilities ----------
Tax assets ----------
Total non-current liabilities 4.1011.417.243.612.170.8972.7239.4333.3221.19
Total current assets 1.181.481.872.022.222.5458.1058.5051.4626.35
Total liabilities 5.9920.8317.3112.245.705.1494.0259.7159.1545.64
Payables 0.250.492.221.032.032.879.7613.6518.3315.29
Other comprehensive income ------0.011.471.792.50
Short-term investments ----------
Retained earnings (deficit) -32.44-37.05-40.16-42.91-49.48-66.03-108.56-149.73-177.02-222.81
Property, Plant & Equipment Net 0.240.110.180.250.210.227.976.896.885.90
Total non-current assets 4.1011.417.243.612.170.8972.7239.4333.3221.19
Other Assets 0.180.170.330.310.290.411.210.910.111.79
Net Debt -6.16-6.80-14.41-24.62-11.85-17.2847.2219.391.90-3.82
Investments ----------
Total shareholders equity 1.883.010.6314.949.9715.82-133.7742.4249.9128.83
Total assets 7.8723.8417.9427.1815.6720.96105.19102.12109.0674.47
Long-term investments ----------
Receivables 0.3415.391.330.231.310.7310.5010.5111.7311.39
Short-term debt 0.02---------

Cash Flow Statement

Download APEN income statement Download APEN income statement
Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Insurance (repayment) of debt ----------
Net Cash/Marketcap 0.000.000.000.000.000.00-0.00-0.00-0.000.00
Insurance (buybacks) of shares ----------
Depreciation & Amortization 0.180.170.140.190.200.228.069.099.729.29
Dividend payments ----------
Operating Cash Flow -1.05-3.598.06-8.31-13.15-15.19-16.00-12.90-13.32-23.12
Acquisitions and disposals -------0.140.20-10.00
Free Cash Flow -1.62-4.057.57-8.66-13.54-15.72-20.77-13.93-14.88-25.07
Net cash flow / Change in cash -1.600.637.6110.21-12.775.4310.34-2.5411.38-6.41
Effect of forex changes on cash -------0.22-0.100.13-0.11
Financing Cash Flow 0.024.690.0318.870.7721.1533.4812.6226.709.70
Investment purchases and sales ----------
Capital Expenditure -0.57-0.47-0.49-0.34-0.39-0.54-4.76-1.03-1.56-1.95
Stock-based compensation 0.591.030.700.600.841.240.470.380.761.40
Investing Cash Flow ----------

Retained Earning Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Retained Earnings (Previous Year) --32-37-40-43-49-66-109-150-177
Net Income 4-5-3-3-7-17-27-41-27-46
Stock Dividends -36------15---
Divident Paid ----------
Retained Earnings -32-37-40-43-49-66-109-150-177-223

PPE Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Year 2009201020112012201320142015201620172018
Gross PPE -000000877
Annual Depreciation 10100113-021
Capital Expenditure -1-0-0-0-0-1-5-1-2-2
Net PPE 0000008776

Intangible and Goodwill Schedule

Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Intangible and Goodwill (Previous Year) -112222495043
New Purchases ----------
Intangible and Goodwill 11222249504315
Apollo Endosurgery Inc.

Apollo Endosurgery Inc. (APEN)

2.66
0 (0.00%)

About


Healthcare
Medical Devices
NASDAQ Global Market

Apollo Endosurgery Inc is a developer of medical devices in the United States. The company's major focus area is obesity and gastrointestinal diseases.